Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06460298 · ClinicalTrials.gov registry record · Phase 1
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
A Phase 1 study of Triple Negative Breast Cancer, sponsored by ProDa BioTech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
- 2
- Study locations
NCT06460298 is a Phase 1 study of Triple Negative Breast Cancer that is actively recruiting participants, run by ProDa BioTech. The registered enrollment target is 51 participants, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06460298, a Phase 1 study of Triple Negative Breast Cancer, is actively recruiting participants, sponsored by ProDa BioTech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase I/II Trial Evaluating the Safety and Efficacy of ProAgio, an anti- αvβ3 Integrin Cytotoxin, in Combination with Gemcitabine in Patients with Metastatic Triple Negative Breast Cancer
Conditions Studied
Interventions
- DRUG ProAgio Dose Levels (DL) 1,2,3,4
- DRUG ProAgio Dose Expansion
Study Locations (2)
Georgia
- Emory University Winship Cancer Institute - Atlanta
- Winship Cancer Institute of Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2024-08-20 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06460298
The ClinicalTrials.gov registry entry for NCT06460298 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (79% lower). The listed sponsor is ProDa BioTech, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which ProAgio Dose Levels (DL) 1,2,3,4 is the first listed.
NCT06460298 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06460298 about?
NCT06460298 is a clinical study titled "ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer". This is a Phase I/II Trial Evaluating the Safety and Efficacy of ProAgio, an anti- αvβ3 Integrin Cytotoxin, in Combination with Gemcitabine in Patients with Metastatic Triple Negative Breast Cancer
What is the current status of trial NCT06460298?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2024-08-20. Estimated completion is 2026-10-01.
What conditions does trial NCT06460298 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer.
What interventions are being tested in trial NCT06460298?
The interventions under investigation include: ProAgio Dose Levels (DL) 1,2,3,4 (DRUG), ProAgio Dose Expansion (DRUG).
Who is sponsoring clinical trial NCT06460298?
This trial is sponsored by ProDa BioTech, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06460298 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.